Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The user is experiencing hair loss and is considering using topical minoxidil and finasteride due to concerns about liver health, specifically elevated ALT levels from fatty liver. They are advised to start with topical treatments while continuing weight loss and dietary changes to improve liver function.

The conversation discusses using a multimodal approach to treat androgenic alopecia, including substances like gamma-linolenic acid, DHA, sulforaphane, melatonin, cetirizine, astaxanthin, fisetin, apigenin, curcumin, limonene, genistein, and berberine. Users also mention using ketoconazole, minoxidil, and low-level laser therapy (LLLT) as part of their hair loss treatment regimens.

User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.

The user is experiencing significant hair loss and has tried treatments like PRP therapy, topical and oral Minoxidil, Finasteride, and dietary changes, with limited success. They are concerned about losing more hair before a scheduled hair transplant and are advised to postpone the transplant to allow medications more time to work.

PP405 is discussed as a potential alternative to finasteride, but its effectiveness and market availability are uncertain. Users share experiences with finasteride, minoxidil, and topical treatments, noting side effects and application techniques.

The conversation lists various topical hair loss treatments combining Minoxidil and Finasteride, ranking them by price and providing details like concentration and availability. The user also mentions personal positive results with a topical Finasteride-only solution.

The conversation is optimistic about future hair loss treatments, highlighting Veradermics, Breezula, and PP405 as promising options expected by 2027-2028. The user expresses hope that these developments will prevent future generations from experiencing the same struggles with hair loss.

Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.

The comparison of 0.5mg dutasteride and 1mg finasteride for treating hair loss in men with androgenetic alopecia, with discussion of which is more effective and has fewer side effects.

PP405 is a new drug in Phase 2 trials for hair loss, generating cautious optimism among users. Some users are currently using finasteride and experiencing side effects, while others are skeptical about unapproved products being sold.

Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.

The user is experiencing increased hair loss and was diagnosed with male pattern baldness. They are considering using oral or topical finasteride to manage the condition and are contemplating cutting their hair short.

PP405 is a potential hair loss treatment that may reactivate dormant hair follicles, with Phase 3 trials expected. Some users are cautious, suggesting using finasteride in the meantime, while others are skeptical about PP405's effectiveness.

Switching from finasteride to dutasteride is discussed, with some users suggesting gradual replacement to potentially improve hair regrowth. OP plans to try replacing one daily use of finasteride with dutasteride to see if it leads to better results.

The conversation is about the effectiveness of hair loss treatments, specifically finasteride and dutasteride, in different populations. Some users believe that the results of Japanese studies may not be relevant to Caucasian men, especially young ones, and that East Asians may respond better to these treatments. Others argue that clinical studies should be the basis for decision-making, while acknowledging that individual responses to medications can vary.

The user discusses switching from multiple vitamins to a single multivitamin pill. They also mention using oral finasteride and topical minoxidil with finasteride for hair loss treatment.

A user is seeking advice on increasing graft survivability after a hair transplant, mentioning PRP, Mesotherapy, Stem Cell injections, and considering L-Arginine before starting Minoxidil. They are looking for ways to support blood flow before applying Minoxidil.

Switching from finasteride to dutasteride, with additional treatments like minoxidil and tretinoin, has not improved hair loss and may have worsened it. Users report better results with finasteride, citing fewer side effects and lower cost.

The conversation discusses the use of finasteride for hair loss, with OP considering switching to dutasteride due to concerns about effectiveness. Users share experiences and concerns about side effects, including potential impacts on fertility.

The user has been using finasteride 0.1% and minoxidil 5% for hair loss with some regrowth but seeks improvement. Suggestions include increasing finasteride dosage, using dutasteride, adding dermarolling, or switching to oral medication.

A private clinic suggests starting with topical Minoxidil only, raising concerns about DHT blocking and potential side effects of Finasteride. The user is considering whether to follow this plan or use a combination of Minoxidil and Finasteride for hair thinning.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

The user is using RU58841, Revivogen, Regenepure ketoconazole shampoo, and plans to use a stimufield cap to address hair loss. They aim to avoid finasteride and minoxidil while hoping to stop hair loss and regrow hair.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

A 21-year-old is experiencing hair thinning and is considering using oral finasteride and minoxidil. They are seeking advice on the cheapest and easiest provider among Drb.ai, ro.co, or Amazon One Medical.

Topical finasteride is less popular due to inconvenience, cost, and availability, while oral finasteride is favored for ease and safety. Some users experience side effects with topical use, but find it effective with minoxidil, though opinions on its efficacy vary.

The user is considering alternatives to topical minoxidil for hair growth due to concerns about future cat ownership, mentioning stemoxydine and redensyl as possibilities. They currently use topical regaine foam and oral finasteride.

The user feels hopeless about hair loss despite using finasteride, dutasteride, minoxidil, and RU58841, and having a hair transplant. They are advised to maintain consistency in treatment, consider increasing dutasteride dosage, and explore topical solutions for better results.

Pelage Pharmaceuticals' PP405, a new hair loss treatment, was recognized by Time Magazine as one of the best inventions of 2025. The conversation expresses optimism about the recognition of this in-development treatment.

RU58841 is not recommended for use around children due to potential exposure risks. Alternatives like CB-03-01 might be considered, but further research is advised.